0.4985
Elevation Oncology Inc stock is traded at $0.4985, with a volume of 398.52K.
It is down -2.27% in the last 24 hours and down -24.36% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.5101
Open:
$0.5041
24h Volume:
398.52K
Relative Volume:
0.19
Market Cap:
$29.52M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.6006
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
-2.43%
1M Performance:
-24.36%
6M Performance:
-18.12%
1Y Performance:
-88.05%
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ELEV
Elevation Oncology Inc
|
0.4985 | 29.52M | 0 | -41.95M | -38.34M | -0.83 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-25 | Initiated | William Blair | Outperform |
May-31-24 | Initiated | Piper Sandler | Overweight |
May-14-24 | Initiated | Stephens | Overweight |
Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
Dec-23-21 | Initiated | H.C. Wainwright | Buy |
View All
Elevation Oncology Inc Stock (ELEV) Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
HC Wainwright Has Optimistic Outlook of ELEV Q1 Earnings - Defense World
Elevation Oncology’s (ELEV) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on Elevation Oncology stock By Investing.com - Investing.com UK
Elevation Oncology stock holds $7 target at JMP Securities By Investing.com - Investing.com Canada
Elevation Oncology’s (ELEV) “Overweight” Rating Reiterated at Stephens - Defense World
Buy Recommendation for Elevation Oncology: Promising Pipeline and Strong Financial Management - TipRanks
Elevation Oncology stock holds $7 target at JMP Securities - Investing.com
Elevation Oncology’s (ELEV) Outperform Rating Reiterated at William Blair - Defense World
Analysts Issue Forecasts for ELEV FY2029 Earnings - Defense World
Research Analysts Offer Predictions for ELEV Q2 Earnings - Defense World
Elevation Oncology’s Future in Jeopardy: Financing Challenges Threaten Product Development - TipRanks
Elevation Oncology Reports 2024 Financial Results and Progress - TipRanks
Strategic Advancements and Financial Stability Drive Buy Rating for Elevation Oncology - TipRanks
Elevation Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elevation Oncology reports Q4 EPS (18c), consensus (22c) - TipRanks
Elevation Oncology, Inc. SEC 10-K Report - TradingView
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - Marketscreener.com
Elevation Oncology : Corporate OverviewMarch 2025 -March 06, 2025 at 04:34 pm EST - Marketscreener.com
Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan
Elevation Oncology Inc. (ELEV) reports earnings - Quartz
Elevation Oncology Inc (NASDAQ: ELEV) Declines -8.57%: This $28.32 million Stock Could Go Down -1983.33% - Stocks Register
Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges - Investing.com India
Elevation Oncology Stock Hits 52-Week Low at $0.5 Amid Challenges By Investing.com - Investing.com South Africa
Elevation Oncology (ELEV) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Elevation Oncology Inc’s (ELEV) Stock Is Harder To Predict Than You Think - Stocks Register
Elevation Oncology to Participate in Upcoming Investor Conferences - Citizentribune
Can Elevation Oncology's March Conference Appearances Reveal New Cancer Treatment Progress? - StockTitan
Brokerages Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $7.20 - Defense World
Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - Finansavisen
Former Elevation Oncology CSO Joins Aadi to Lead $100M ADC Portfolio Expansion - StockTitan
Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by SG Americas Securities LLC - Defense World
Are Elevation Oncology Inc (ELEV) shares a good deal now? - US Post News
Analysts Offer Predictions for ELEV Q2 Earnings - Defense World
Keeping an Eye on Elevation Oncology Inc (ELEV) After Insider Trading Activity - Knox Daily
Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.63, Up/Down -5.85 - The Dwinnex
Brokers Offer Predictions for ELEV Q1 Earnings - Defense World
Goldman Sachs Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com
JPMorgan Chase & Co. Raises Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
BlackRock, Inc. Increases Stake in Elevation Oncology Inc - GuruFocus.com
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Understanding ELEV stock ratios for better investment decisions - US Post News
Elevation Oncology announces CSO departure By Investing.com - Investing.com South Africa
Elevation Oncology announces CSO departure - MSN
Daiichi Sankyo to promote Okuzawa to CEO - BioCentury
Elevation Oncology Chief Scientific Officer Announces ResignationOn January 29, 2025, Elevation Oncology, Inc. (NASDAQ: ELEV) received a communication from David Dornan, Ph.D., the company’s Chief Scientific Officer, regarding his decision to resign - Defense World
Elevation Oncology Announces CSO Resignation - TipRanks
Vanguard Group Inc. Reduces Stake in Elevation Oncology Inc. - GuruFocus.com
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $7.20 Consensus PT from Analysts - Defense World
Barclays PLC Has $43,000 Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):